0001562180-23-007979.txt : 20231130
0001562180-23-007979.hdr.sgml : 20231130
20231130160441
ACCESSION NUMBER: 0001562180-23-007979
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20231128
FILED AS OF DATE: 20231130
DATE AS OF CHANGE: 20231130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: IGUCHI KIMI
CENTRAL INDEX KEY: 0001304815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 231455700
MAIL ADDRESS:
STREET 1: 100 FOXBOROUGH BOULEVARD
STREET 2: SUITE 240
CITY: FOXBOROUGH
STATE: MA
ZIP: 02035
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2023-11-28
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001304815
IGUCHI KIMI
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
CFO & Treasurer
false
Common Stock
2023-11-28
4
A
false
3500.00
0.00
A
69730.00
D
Common Stock
2023-11-28
4
F
false
943.00
19.27
D
68787.00
D
On March 25, 2020, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 8,750 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on November 28, 2023, resulting in the vesting of the PSUs as to 3,500 shares.
Reflects beneficial ownership balance which includes 670 shares purchased on June 30, 2023 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
2023-11-30
EX-24
2
kimiiguchipoa2019.txt
KIMI IGUCHI POA 2019
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (SVP, General Counsel), Erin Lanciani (SVP, People and
Organizational Strategy), and Jennifer Fitzpatrick (Vice President,
Corporate Counsel) for as long as they remain employees of Sage
Therapeutics, Inc., and Laurie Burlingame of Goodwin Procter, each
acting singly, or their successors in role, to take the following
actions, acting as my agent and attorney-in-fact, with full power of
substitution:
(1) to prepare and sign on my behalf any Form 3, Form 4 or
Form 5 pursuant to Section 16 of the Securities Exchange Act of 1934,
as amended, and to file the same with the Securities and Exchange
Commission, NASDAQ, NYSE, and each stock exchange on which shares of
Common Stock or other securities of Sage Therapeutics, Inc. are
listed, as required by law;
(2) to prepare and sign on my behalf any Form 144
pursuant to the Securities Act of 1933, as amended, and to file the
same with the Securities and Exchange Commission, NASDAQ, NYSE, and
each stock exchange on which shares of Common Stock or other
securities of Sage Therapeutics, Inc. are listed, as required by law;
and
(3) take any other action necessary or proper in
connection with the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am an executive officer
or director of Sage Therapeutics, Inc., and shall not be affected by
my subsequent disability or incompetence. I may revoke this Power of
Attorney by written notice delivered, in person or by nationally
recognized courier, to the attention of the SVP, General Counsel of
Sage Therapeutics, Inc.
/s/ Kimi Iguchi
___________________________________________________
(Signature of Executive Officer or Director)
Name: Kimi Iguchi, Chief Financial Officer
Date: 1/23/2019